Botulinum Toxin Injection with Conjunctival Microincision for the Treatment of Acute Acquired Comitant Esotropia and Its Effectiveness

Table 2

Summary of patient data.

Patient no.	Sex	Age at Onset（years）	Onset to BTXA (wks)	BCVA,Rt/Lt	Cycloplegic refraction(SE)		Angle pre-BTXA (PD)		Angle 6 mos post-BTXA (PD)		Final angle (PD)		Stereo pre-BTXA	Stereo at 6 mos	Final stereo	Follow-up period (mos)	Recurrence
					Rt(D)	Lt(D)	Near	Distance	Near	Distance	Near	Distance
1	M	4	5	0.8/0.8	+1.75	+2.25	30	30	0	15	0	15	40	40	40	17	+
2	M	4	8	0.8/0.8	+1.50	+1.50	60	50	−2	0	−2	0	100	32	32	24	−
3	M	6	20	0.8/0.8	+2.00	+2.00	50	60	0	0	0	0	3000	100	100	18	−
4	M	6	3	1.0/1.0	+1.25	+1.25	50	50	0	0	0	0	100	25	25	11	−
5	M	7	5	0.8/0.8	+2.00	+2.00	40	40	0	3	0	3	400	100	100	8	−
6	F	8	5	1.0/1.0	+2.00	+2.00	70	80	0	0	0	0	400	100	100	12	−
7	M	8	12	1.0/1.0	+1.75	+2.25	40	50	0	0	0	0	200	100	100	10	−
8	M	8	4	1.0/1.0	+1.00	+1.00	50	60	0	0	0	0	63	32	32	18	−
9	M	9	24	1.0/1.0	+0.75	+0.75	80	60	0	0	0	0	400	100	100	7	−
10	M	10	1	1.0/1.0	+0.50	+0.50	40	40	0	0	0	0	100	32	32	12	−
11	M	12	8	1.0/1.0	+1.25	+1.50	20	25	−3	0	−3	0	160	160	160	8	−
12	F	12	8	1.0/1.0	−0.50	+0.50	20	25	−2	0	0	0	32	25	25	8	−
13	M	12	12	1.0/1.0	−4.00	−3.75	40	30	0	0	30	25	160	160	160	10	+
14	M	13	12	1.0/1.0	−2.75	−1.00	50	50	0	9	0	9	160	160	160	7	−
15	M	13	48	1.0/1.0	−4.50	−4.25	40	40	0	0	0	0	160	40	40	7	−
16	M	16	24	1.0/1.0	−3.75	−3.25	25	30	−2	0	−2	0	50	50	50	17	−
17	M	16	12	1.0/1.0	−2.75	0.00	40	30	0	0	0	0	400	50	50	13	−
18	M	16	1	1.0/1.0	0.00	0.00	30	30	0	0	0	0	400	400	400	18	−
19	M	17	12	1.0/1.0	−7.50	−7.50	30	30	−2	0	−2	0	50	50	50	12	−
20	M	17	1	1.0/1.0	+1.00	+1.25	75	80	0	0	0	0	3000	400	400	16	−
21	F	17	16	1.0/1.0	−3.00	−3.75	10	20	0	0	0	0	50	32	32	9	−
22	M	17	48	1.0/1.0	−4.75	−4.50	15	20	3	8	3	8	25	25	25	9	−
23	M	17	96	1.0/1.0	+1.50	+1.00	50	50	0	0	0	0	32	32	32	9	−
24	F	18	24	1.0/1.0	−3.75	−3.50	60	65	15	15	15	15	25	25	25	7	+
25	M	18	4	1.0/1.0	−3.75	−3.25	20	20	0	3	0	3	32	25	25	17	−
26	M	19	24	1.0/1.0	−3.50	−3.25	15	25	−2	0	−2	0	63	63	63	9	−
27	F	29	48	1.0/1.0	−1.50	−1.50	15	20	−2	0	−2	0	160	160	160	19	−
28	F	30	28	1.0/1.0	−1.00	−2.25	30	30	15	20	15	20	20	20	20	7	+
29	F	34	20	1.0/1.0	−6.75	−6.25	20	25	0	15	0	15	20	20	20	19	+

F: female, M: male, BTXA: botulinum toxin A, BCVA: best corrected visual acuity, Rt: right, Lt: left, SE: spherical equivalent, D: diopter, PD: prism diopters.